-
Skyline Medical Inc (NASDAQ: SKLN) shares dropped
19.3 percent to $3.50. Skyline Medical shares have jumped 20.08 percent over the past 52 weeks, while the S&P 500 index has
gained 6.39 percent in the same period.
-
Cancer Genetics Inc (NASDAQ: CGIX) shares
declined 15.6 percent to $1.35.
-
BOS Better OnLine Sol (USA) (NASDAQ: BOSC) fell
13.2 percent to $2.04. BOS Better Online Solutions posted a Q3 loss of $0.08 per share.
-
Fang Holdings Ltd (NYSE: SFUN) shares declined 11.1
percent to $3.05. Fang Holdings posted a Q3 loss of $0.01 per share on revenue of $250.1 million.
-
Alder Biopharmaceuticals Inc (NASDAQ: ALDR) fell
10.1 percent to $24.10 after the company disclosed that it has initiated its PROMISE 2 trial.
-
Ocular Therapeutix Inc (NASDAQ: OCUL) dropped 9.5
percent to $10.41 after gaining 7.18 percent on Friday.
-
Advanced Accelerator Application SA(ADR) (NASDAQ: AAAP) dropped 9.1 percent to $30.72. Advanced Accelerator Applications reported
a Q3 loss of $7 million on revenue of $30.0 million.
-
PhotoMedex Inc (NASDAQ: PHMD) shares fell 9.1
percent to $2.19 after jumping 46.15 percent on Friday.
-
Signal Genetics Inc (NASDAQ: SGNL) shares
declined 7.8 percent to $8.72. Signal Genetics disclosed that it has regained compliance with the NASDAQ minimum bid price
listing requirement.
-
H & R Block Inc (NYSE: HRB) fell 7.5 percent to
$22.19. BTIG Research downgraded H & R Block from Neutral to Sell.
-
Tupperware Brands Corporation (NYSE: TUP) declined 5
percent to $56.35. B. Riley downgraded Tupperware from Neutral to Sell.
-
Curis, Inc. (NASDAQ: CRIS) dropped 4.8 percent to
$3.21. Curis reported the full approval of Roche's Erivedge in the European Union.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.